Breast Cancer

The FDA has approved palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Gabriel N. Hortobagyi, MD, who has pioneered many clinical advances in the treatment of women with breast cancer, was honored in the Breast Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Although metastatic breast cancer remains incurable for most women, recent research offers important new guidance for clinicians managing patients across the spectrum of advanced disease.

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes.

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.